---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000054"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:28:51.874374+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track

## Summary
- Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.
- Revenue $16M from Théa Open Innovation upfront; net income $13.5M vs. $1.9M loss YoY.
- Phase 2 ABACUS-2 trial for KIO-301 (retinitis pigmentosa) on track for Q4 2024 start.
- Phase 2 trial for KIO-104 (retinal inflammation) expected to begin in 2025.
- TOI deal includes up to $285M milestones and tiered royalties up to low-20% on sales.

## SEC filing metadata
- accession: 0001372514-24-000054
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000054/0001372514-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000054/kprx-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000054
- JSON: https://secwatch.observer/filing/0001372514-24-000054.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000054.txt

## Key facts
- Earnings Releases
  KIORA PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $16.0 million, net income $13.5 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $16.0 million
  - Net income: $13.5 million
  - Result: reported results
  source text: Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI. General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. N
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000054/0001372514-24-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.